Hansa Biopharma AB
OTC:HNSBF

Watchlist Manager
Hansa Biopharma AB Logo
Hansa Biopharma AB
OTC:HNSBF
Watchlist
Price: 2.91 USD Market Closed
Market Cap: 317.7m USD

Wall Street
Price Targets

HNSBF Price Targets Summary
Hansa Biopharma AB

Wall Street analysts forecast HNSBF stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HNSBF is 7.17 USD with a low forecast of 3 USD and a high forecast of 10.49 USD.

Lowest
Price Target
3 USD
3% Upside
Average
Price Target
7.17 USD
146% Upside
Highest
Price Target
10.49 USD
260% Upside
Hansa Biopharma AB Competitors:
Price Targets
688687
Beijing Kawin Technology Share-holding Co Ltd
79% Upside
VCEL
Vericel Corp
50% Upside
ORY
Oryzon Genomics SA
129% Upside
2171
CARsgen Therapeutics Holdings Ltd
41% Upside
006280
Green Cross Corp
20% Upside
LCTX
Lineage Cell Therapeutics Inc
175% Upside
688177
Bio-Thera Solutions Ltd
43% Upside
ENTA
Enanta Pharmaceuticals Inc
51% Upside

Revenue
Forecast

Revenue Estimate
Hansa Biopharma AB

For the last 13 years the compound annual growth rate for Hansa Biopharma AB's revenue is 46%. The projected CAGR for the next 4 years is 78%.

46%
Past Growth
78%
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Hansa Biopharma AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
Hansa Biopharma AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-61%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HNSBF's stock price target?
Price Target
7.17 USD

According to Wall Street analysts, the average 1-year price target for HNSBF is 7.17 USD with a low forecast of 3 USD and a high forecast of 10.49 USD.

What is Hansa Biopharma AB's Revenue forecast?
Projected CAGR
78%

For the last 13 years the compound annual growth rate for Hansa Biopharma AB's revenue is 46%. The projected CAGR for the next 4 years is 78%.

Back to Top